Acompanhe as Notícias da Recifes

Researchers at the University of California San Diego and their colleagues have identified a key cellular pathway that drives brain degeneration in both a rare childhood disorder and the far more common Alzheimer's disease.

Ensaio clínico sugere que, ao diminuir níveis da proteína tau, pacientes tenham um melhor prognóstico; diretora médica da farmacêutica explica. Destaque: 65%, 54%, 15%.

What if certain signs of the disease were to manifest subtly during sleep, long before the first memory problems appear? This is the line of inquiry being explored by a team of researchers at ULiège.

In Alzheimer's disease, amyloid plaques form in the brain, followed by threadlike structures made of the protein tau.

Ainda não há uma resposta conclusiva a respeito. Mas o uso prolongado desses medicamentos está associado a vários efeitos adversos sobre a cognição.

The brain's immune cells are increasingly recognized as key players in Alzheimer's disease, but exactly how they change as the disease develops has remained unclear. A new study published in Nature Genetics provides the most comprehensive map to date of these cells, identifying a

Alzheimer's disease may look similar from one person to another even when different biological processes are driving the damage, according to a new study led by researchers at the University of California, Irvine.

As new Alzheimer's drugs move from clinical trials into everyday care, families are asking whether these treatments are safe, how long patients can stay on them and whether they truly slow the disease outside tightly controlled studies.

Australians have seen a flurry of headlines announcing the arrival of blood tests for Alzheimer's disease. O recorte ajuda a contextualizar a pauta dentro de Saúde.

In a longitudinal study conducted at Vanderbilt Health, including investigators from the Vanderbilt Memory and Alzheimer's Center (VMAC), researchers found that lower cardiac output is associated with accelerated cerebral atrophy among older adults who carry the APOE-e4 allele, a

Beginning around age 50, the brain’s memory center appears to lose many of its longtime immune cells and replace them with more inflammatory ones. This surprising shift may help explain how normal aging sets the stage for Alzheimer’s disease and dementia.

Many people with less common forms of Alzheimer's disease may not qualify for newer anti-amyloid treatments designed to slow the disease, according to a study published Aug. 5, 2026, in Neurology.